Eli Lilly & Co.'s plan to add a new use in ankylosing spondylitis for its Interleukin-17A (IL-17A) inhibitor Taltz is on track, following the announcement of positive results from COAST-V, the first of three Phase III studies for this indication.
Taltz (ixekizumab) has been approved for moderate-to-severe psoriasis since March 2016 and psoriatic arthritis since December 2017. Also see "







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)